- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
- Interventions
- Selpercatinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 5,157
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastro-Intestinal Cancer
- Interventions
- Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Hamilton, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey + 2 more
- Conditions
- Chronic Neck Pain
- Interventions
- Quantitative Ultrasound, Osteopathic TART Assessment, Osteopathic Manipulation Treatment
- Diagnostic Test · Procedure
- Lead sponsor
- Rocky Vista University, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Ivins, Utah
- Conditions
- Esophageal Cancer
- Interventions
- ArabinoFuranosylGuanine [18F]F-AraG
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Nashville, Tennessee • Houston, Texas
- Conditions
- Brain Tumor, Head and Neck Cancer
- Interventions
- substructure informed planning, Neurocognitive Testing, MRI
- Radiation · Other · Diagnostic Test
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2035
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Head and Neck Cancer
- Interventions
- Intensity Modulated Radiation Therapy
- Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Gastric Cancer, Colon Cancer, Esophageal Cancer, Rectal Cancer, Pancreatic Cancer, Gastrointestinal Cancer
- Interventions
- Phase 2 Intervention - Geriatric Co-Management
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cervical Cancer
- Interventions
- Questionnaires, Biological Samples
- Behavioral · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 285 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Neoplasms, Oral, Mouth Neoplasms
- Interventions
- GSK1120212
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Prostate Cancer, Recurrent Adenocarcinoma, Liver Cancer, Head and Neck Cancer
- Interventions
- MRI Simulator, Radiation Therapy
- Device · Radiation
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Spinal Cord Injury Cervical
- Interventions
- Blood flow-restricted resistance exercise
- Behavioral
- Lead sponsor
- Quality Living, Inc.
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Face and Neck Wrinkles, Texture, Pigmentation
- Interventions
- Lutronic Infini System, Lutronic LaseMD System
- Device
- Lead sponsor
- CynosureLutronic
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Vista, California • Santa Rosa Beach, Florida
- Conditions
- Solid Tumors
- Interventions
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
- Conditions
- Esophageal Cancer, Lung Cancer, Chest Wall Disorders
- Interventions
- Dexmedetomidine
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Diabetes, Cervical Myelopathy, Cervical Spondylosis
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Cetuximab, Intensity-Modulated Radiation Therapy, Ipilimumab, Laboratory Biomarker Analysis
- Biological · Radiation · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Head and Neck Cancer
- Interventions
- 46 Gy Radiation Therapy, 40 Gy Radiation Therapy, 35 Gy Radiation Therapy
- Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- The Primary Outcome is Preterm Delivery Before 28 Weeks Gestational Age Compared to Women With One vs Two Cerclages Placed
- Interventions
- Double cerclage, Single cerclage
- Procedure
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Thyroid Cancer
- Interventions
- RAD001
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- HPV Infection
- Interventions
- 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
- Biological
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Industry
- Eligibility
- 24 Years to 64 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
- Interventions
- Durvalumab, Cetuximab
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Skin Laxity
- Interventions
- Ulthera System Treatment
- Device
- Lead sponsor
- Ulthera, Inc
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Gastrointestinal Mucositis (Defined as Mucositis Involving the Mouth, Esophagus, or Small Intestine)
- Interventions
- Not listed
- Lead sponsor
- TRIAD Burden of Illness
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin